Barclays analyst Etzer Darout raised the firm’s price target on CytomX Therapeutics (CTMX) to $6 from $3.50 and keeps an Overweight rating on the shares. The company’s data in late-line colorectal cancer compares favorably to peers, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics appoints Rachael Lester as chief business officer
- Oppenheimer positive on CytomX after Merus colon cancer data
- CytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential
- CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
- CytomX Therapeutics assumed with an Overweight at Barclays